Unresectable Extrahepatic Bile Duct Cancer Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0028791 (Unresectable Extrahepatic Bile Duct Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00033462Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerTreatment
NCT00356889Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsTreatment